May 26, 2016
The multicenter, randomized Survey of Inhibitors in Plasma-Product Exposed Toddlers, or SIPPET study, presented at the ASH Annual Meeting and Exposition, which demonstrated that recombinant Factor VIII products may lead to a 1.87-fold increased risk for the development of an inhibitor compared with plasma-derived products among patients with severe hemophilia A, represents “significant” results that impact the therapeutic choices made about the different Factor VIII products.
“This is quite a significant finding. Inhibitors are a very serious problem for patients with hemophilia,” according to Ulrike M. Reiss, MD, associate faculty member and director of clinical hematology and the hemophilia treatment center at St. Jude Children’s Research Hospital. “They basically neutralize any infused factor and, therefore, there is no optimal way of treating, and stopping, bleeding.”